- The European Commission granted marketing authorization to Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) 2026-2027 COVID-19 vaccine formula targeting the new XFG variant, which peaked at 74 per cent of infections globally in October 2025.
- Manufacturing is now underway, with the vaccine under consideration by regulatory authorities across the world.
- Shares of Pfizer and BioNTech have fallen by 41.25 per cent and 71.66 per cent, respectively, over the past five years.
The European Commission granted marketing authorization to Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) 2026-2027 COVID-19 vaccine formula targeting the new XFG variant – which peaked at 74 per cent of infections globally in October 2025 – in individuals 6 months of age and older.
The vaccine is based on BioNTech’s proprietary mRNA technology, which has informed more than five billion doses of COVID-19 vaccines to date.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
The authorization, valid in all 27 EU member states, as well as Iceland, Norway and Liechtenstein, follows evidence submissions on the part of Pfizer and BioNTech to the European Medicines Agency supporting vaccine safety and efficacy, including strong immune responses against circulating SARS-CoV-2 lineages such as XFG, XFG.1.1, NB.1.8.1, PQ.17 and PQ.2.8.1, among others.
According to Wednesday’s news release, Pfizer and BioNTech have begun manufacturing in anticipation of the colder months ahead, concurrently submitting vaccine data to regulatory authorities around the world.
About Pfizer
Pfizer is a global biopharmaceutical company building upon a more than 175-year history of innovating within and expanding access to affordable health care.
Pfizer stock (NYSE:PFE) last traded at US$25.15, adding 3.50 per cent year-over-year, while giving back 41.25 per cent since 2021.
About BioNTech
BioNTech is a forward-looking biopharmaceutical company advancing investigative therapies for cancer and other serious diseases.
BioNTech stock (NASDAQ:BNTX) last traded at US$92.95, giving back 16.62 per cent year-over-year and 71.69 per cent since 2021.
Join the discussion: Find out what investors are saying about these biopharmaceutical stocks on the Pfizer Inc. and BioNTech SE Bullboards and make sure to explore the rest of Stockhouse’s stock forums and message boards.